|
Guest
|
Angiogenesis inhibitors in breast cancer therapy
A detailed description of angiogenesis inhibitors (bevacizumab,
sunitinib, vandetanib, pazopanib, ramucirumab, ABT-869, AV-951,
PTC299, AMG 386, aflibercept) that are currently used in routine
therapy or are in clinical trials in breast cancer patients.
In the book « Molecular Therapy of Breast Cancer: Classicism Meets
Modernity ».
by Marc Lacroix
InTextoResearch, Baelen (Liège, Wallonia), Belgium
Nova Sciences Publishers, New York, ISBN 978-1-60741-593-0
https://www.novapublishers.com/catalog/product_info.php?cPath=23_29&products_id=10042&osCsid=8fed1efc6158a0ba4004bec047b66ff0 |
|
|
